A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adult Subjects With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
This study is to evaluate the efficacy and safety of GS-6624 on bone marrow fibrosis either
alone or in combination with ruxolitinib in participants with Primary myelofibrosis (PMF)
and Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis (ET/PV MF).
The study is designed as a two stage trial. In the stage 1, patients will be randomized into
two cohorts to receive either 200 or 700 mg of study drug. In the stage 2, patients on
ruxolitinib will be randomized to receive either 200 or 700 mg of study drug.
Study Status: Active, not recruiting
Information provided by:
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Zung Thai, MD, PhD., Study Director